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Intrauterine adhesions (IUAs) caused by endometrial injury have a serious impact on women’s fertility and mor-
bility and involves a wide range of patients. Although the first case of IUAs was published in 1984 by Heinrich 
Fritsch, a full description of Asherman syndrome was done by Joseph Asherman. IUAs lead to a lot of complica-
tions in women, as the partial or complete closure of the uterine cavity, which may result in symptoms including 
abnormal menstruation, pelvic pain, recurrent pregnancy loss, secondary infertility, and pregnancy complications. 
Hysteroscopy, which has relegated blind curettage, is currently considered the gold standard diagnostic and thera-
peutic approach also as for outpatients. However, an integrated approach, including preoperative, intraoperative 
and postoperative procedures is needed to improve the reproductive outcome of the complex syndrome. In the 
post-operative care, the patient can benefit from some therapeutic and prophylactic methods used alone or in 
combination with each other. In this review, authors discuss on the efficacy of traditional methods for the preven-
tion of complications of IUAs after surgery, such as hormonal therapy, physical barriers, vasodilators and antibi-
otics, as well as novel strategies such as stem cell therapy and novel therapeutic agents. 
 





Intrauterine adhesions (IUAs) are a result of me-
chanical or infectious injury to the basalis layer 
of the endometrium, caused by curettage, hyster-
oscopic surgery, uterine artery embolization, B-
Lynch sutures, abdominal myomectomy, hyster-
oscopic myomectomy, genital tuberculosis and 
surgical treatment of Mullerian anomalies 
(Doroftei et al. 2020).  
In some women, the normal repair mechanisms 
of the endometrium are aberrant, including hy-
poxia, reduced neovascularization and altered 
expression of adhesion-associated cytokines, re-
sulting in IUAs formation (Buttram et al. 1988). 
IUAs can lead to partial (Figure 1) or complete 
obliteration of the cervix and the uterine cavity, 
which may result in clinical sequelae including 
abnormal menstruation, amenorrhea, pelvic 
pain, infertility (caused by the obstruction of 
sperm transport into the cervix, impaired em-
bryo migration within the uterine cavity and fail-
ure of embryo implantation (Dreisler and Kjer 
2019)), recurrent pregnancy loss and pregnancy 
complications. 
The traditionally widely used classification sys-
tem of the IUAs is the American Fertility Society 
(Buttram et al. 1988) score (Figure 2), classifying 
IUAs in three stages: mild (grade I), moderate 
(grade II), and severe (grade III). 
Currently, Hysteroscopy can be considered the 
gold standard for diagnostic and therapeutic ap-
proach also for outpatients. The occurrence of 
new adhesions after primary hysteroscopic adhe-
siolysis is so much frequent and the recurrence 
rate is associated with the grade of adherences 
(Figure) as found by Hanstede et al, that re-
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ported 21%–25% recurrence with grade 1–2 ad-
herences, 29.1% with grade 3, 38.5% with grade 
4, and 41.9% with grade five (Bosteels et al. 
2015).  
Although numerous observational studies sug-
gest potential benefit with the use of anti-adhe-
sion therapies (intrauterine device or balloon, 
hormonal treatment, antibiotics, barrier gels or 
human amniotic membrane grafting) for de-
creasing IUAs, currently, there are no strong rec-
ommendation in favor of the use of anti-adhe-
sion therapies after operative hysteroscopy. 
At present the effectiveness of the anti-adhesion 
treatment following operative hysteroscopy for 
decreasing IUAs remains uncertain as suggested 
the Cochrane Review of 2017, because of the 








Figure 2. Classification system of the Intra Uterine Adhesions 
of the American Fertility Society (AFS). 
 
1.2. Prevention of adhesion recurrence  
 
Adhesions recurrence after surgery is one of the 
most important factors which can delay repro-
ductive outcome after IUA treatment. Adhe-
sions recurrence rate is significantly higher in 
those cases where a severe AS is diagnosed  
(Figures 3 and Figure 4).  
Several methods to prevent IUA reformations 
after surgery have been proposed. Nonetheless 
few comparative studies have been developed 
(Xu et al. 2018). This could be probably due to 
the multitude treatment approach adopted and 
particularly to the lack of a unified standardized 




Figure 3. The image shows a hysteroscopy with resectoscope 
for ablation of intrauterine adhesions in a patient with Asher-
man syndrome. 




Figure 4. Uterine cavity cleaned after ablation of intrauterine 
adhesions. 
 
1.3. Intrauterine device 
 
The intrauterine device (IUD) may provide a 
physical barrier between the uterine walls, sepa-
rating the endometrial layers to prevent their fu-
sion during the initial healing phase (Buttram et 
al. 1988).  
The characteristics of IUD to prevent intrauter-
ine adhesion formation should be the tolerability 
of the device, the suppression of IUA formation 
and the restoring of healing of the endometrium. 
There are several observational studies that rec-
ommended the insertion of a device after lysis of 
IUAs such as IUD and Foley catheter balloon 
after lysis of IUAs or septoplasty.  
There are different kinds of IUD (copper‐con-
taining IUD, T‐shaped IUD, loop IUD) with 
particular characteristics and mechanism of ac-
tions, also, there are no sizes of IUD available 
for too large or too small uterine cavities (Koda-
man and Arici 2007).  
 
1.4. Intrauterine balloons 
 
An intrauterine balloon stent is another mechan-
ical method frequently used to prevent the refor-
mation of adhesions. The Cook Medical balloon 
(Indianapolis, IN, USA) has designed a heart-
shaped intrauterine balloon for prevention of 
secondary intrauterine adhesions thanks to its 
triangular shape, which conforms to the config-
uration of a normal uterus and maintain separa-
tion at the margins of uterine cavity (March 
2011).  
 
1.5. Foley catheters 
 
A standard pediatric Foley catheter is another 
commonly used method to prevent recurrence 
of IUAs.  
In a randomized controlled trial, Lin et al com-
pared the efficacy of intrauterine balloon (re-
moved after 7 days) and IUD demonstrating 
similar efficacy (Lin et al. 2015). 
Orhue et al compared an IUD with a pediatric 
Foley catheter and found that the catheter was a 
safer and more effective adjunctive method of 
treatment of IUA compared with the IUD. The 
persistent post-treatment amenorrhea and hypo-
menorrhea occurred less frequently in the Foley 
catheter group (18.6%) than in the IUD group 
(37.3%) (P<0.03), and the conception rate in the 
catheter group was 33.9% compared with 22.5% 
in the IUD group. The need for repeated treat-
ment was also significantly less in the Foley cath-
eter group (Orhue, Aziken, and Igbefoh 2003). 
Recently, Shi et al compared the efficacy of in-
termittent intrauterine balloon dilatation versus 
standard care in the prevention of adhesion 
reformation in two hundred patients with mod-
erate to severe IUAs who underwent hyster-
oscopic adhesiolysis. In this randomized con-
trolled trial, the balloon group received intrauter-
ine balloon dilatation therapy at 2 weeks and 6 
weeks after surgery, whereas the control group 
did not. A total of 191 patients successfully com-
pleted the study protocol (94 cases for the bal-
loon group and 97 cases for the control group). 
According to hysteroscopic evaluation at the 8th 
week, the overall adhesion reformation rate was 
significantly lower in patients in the balloon 
group than patients in the control group (20.2% 
versus 40.2%, respectively; P < 0.05).  
This study shows that postoperative intermittent 
intrauterine balloon dilatation therapy can signif-
icantly reduce postoperative adhesion refor-
mation and significantly increase menstruation 
flow (Shi et al. 2019). 
Recently Huang at al have patented intrauterine 
stent of various sizes, flexible and thin, but at the 
moment their studies have been performed on a 
small number of patients with moderate or se-
vere IUAs and so we have no encouraging data 
(Huang et al. 2020). 
 
1.6. Anti-adhesion barrier 
Hyaluronic acid-derived products showing a 
possible role in gynecologic surgery to prevent 
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intra-abdominal IUAs, reducing the risk of ad-
hesion recurrence after surgical treatment of 
IUAs (Guida et al. 2004; Tsapanos et al. 2002; 
Acunzo et al. 2003), but may not be suitable 
alone for endometrial surfaces due to a short 
half-life and weak attachment to the endome-
trium (Acunzo et al. 2003). The material usually 
needs to be used in combination with other de-
vices.  
Use of biodegradable gel surgical barriers is 
based on the principle of keeping adjacent 
wound surfaces mechanically separate (Renier et 
al. 2005). The exact mechanisms by which ACP 
(auto-cross-linked polysaccharide) and HA‐
CMC (sodium hyaluronate and carboxymethyl-
cellulose gel) can reduce adhesion reformation 
are not well known but may be related to 'hydro 
flotation' or 'siliconizing' effects. Hyaluronic acid 
gel or polyethylene oxide-sodium carbox-
ymethylcellulose gel for the prevention of intra-
uterine adherences have been investigated 
demonstrating conflicting results. Acunzo et al 
found a significant effect of hyaluronic acid 
compared to no treatment (14% versus 32%) 
(Acunzo et al. 2003). Instead, Lin et al demon-
strated that the balloon and IUCD were more 
effective than hyaluronic acid (Lin et al. 2015). 
Ducarne et al compared application of ACP gel 
(30 women) versus no gel (24 women) at the end 
of an operative hysteroscopic procedure per-
formed to treat myomas, polyps, uterine septa or 
IUAs, finding no statistically significant differ-
ences between comparison groups in the rate of 
adhesion formation, or in mean adhesion scores 
and severity of adhesions (Ducarme et al. 2006).  
Different results were obtained from the recent 
meta-analysis conducted by Fei et al. finding a 
significant reduction of the incidence of moder-
ate and severe IUAs (RR 0.18, 95% CI: 
0.07~0.47; p=0.0004) and an improvement in 
the pregnancy rate after miscarriage (RR 1.94, 
95% CI 1.46~2.60; p<0.00001) with the use of 
hyaluronic acid gel (Zheng et al. 2020).  
 
1.7. Human amniotic membrane grafting 
 
Human amniotic membrane HAM is the inner-
most layer of the fetal membranes and possess 
many properties that make them suitable for use 
in regenerative medicine, such as low immuno-
genicity, anti-fibrotic, anti-inflammatory, angio-
genic and anti-angiogenetic and anti-microbial 
properties (Gary and Jones, 2017). HAM acts as 
a biologically active mechanical barrier to sup-
press adhesion formation while promoting en-
dometrial healing (Amer and Abd-El-Maeboud 
2006), through regeneration of epithelium facili-
tating migration of epithelial cells, reinforcing 
adhesion of the basal epithelium, promoting ep-
ithelial cell differentiation (Meller and Tseng 
1999), preventing cellular apoptosis (Hori et al. 
2006), producing factors or creating a microen-
vironment for effective tissue repair and endo-
metrial regeneration, possibly by stimulating en-
dogenous stem cells (Padykula 1989). 
According to a randomized controlled trials of 
Zheng et al including 300 patients, which evalu-
ated the ability of HAM to prevent the recur-
rence of IUAs after hysteroscopic adhesiolysis, 
the use of HAM increased menstrual blood vol-
ume (mean difference 6.15, 95% CI 4.20–8.11; 
P<0.001) but failed to improve the rate of intra-
uterine adhesion recurrence or spontaneous 
abortion (Zheng et al. 2018). 
Yan et al in a network Meta-Analysis of random-
ized controlled trials has found a significant ad-
vantage with the use of freeze-dried amniotic 
agents plus a balloon to reduce IUAs recurrence 
and IUAs scores after adhesiolysis (Yan and Xu 
2018).  
A prospective randomized controlled trial con-
ducted among 88 women with severe IUA who 
underwent hysteroscopic adhesiolysis analyzed 
the efficacy of freeze-dried amnion graft covered 
the balloon portion of the Foley catheter for pre-
vention of IUAs. Also, this study concluded that 
the use of HAM was effective in improving men-
struation, but the rates of IUAs reformation and 
pregnancy were not significantly different (Gan 
et al. 2017). 
 




In recent years, many studies described use of 
medications to increase vascular flow to endo-
metrium such as aspirin, nitroglycerine and 
sildenafil citrate. But evidence was insufficient to 
show whether vasodilators increase the live birth 
rate (Gutarra-Vilchez et al. 2018).  
Studies have demonstrated that aspirin com-
bined with estrogen may significantly prevent 
the postoperative disease recurrent rate, improve 
Sarah Gustapane, Sara Cavalera, Ottavia D’Oria, Andrea Tinelli 
 
35 
endometrial receptivity and improve the concep-
tion rate by increasing endometrial blood supply 
and angiogenesis more effectively. The aspirin 
inhibits endometrial fibrosis by suppressing the 
TGF- 1-Smad2/Smad3 pathways (Z. Zhang et 
al. 2020). 
Zinger reported two cases of woman with his-
tory of a postpartum uterine curettage, inade-
quate endometrium thickness after surgical re-
section of IUAs that are treated with sildenafil 
citrate and with the results of having achieved 
pregnancy (Zinger, Liu, and Thomas 2006).  
However, the number of women treated using 
these therapies remains small, and because all 
such treatment is off label, these medications 





There is no clear recommendation in the litera-
ture on whether it is necessary to use prophylac-
tic antibiotics for minor operative procedures 
such as dilatation and curettage for evacuation of 
conceptive products, fractional curettage for ab-
normal uterine bleeding, hysterosalpingography 
for infertility evaluation and hysteroscopy for in-
trauterine cavity diagnosis and treatment. 
The Cochrane of 2013 regarding the prophylac-
tic antibiotics for transcervical intrauterine pro-
cedures versus placebo concluded that there are 
no randomized controlled trials that asses the ef-
fects of prophylactic antibiotics on infection 
complications and therefore is not possible to 
draw any conclusions (Thinkhamrop, Laopai-
boon, and Lumbiganon 2007). However, when 
obvious infection is seen, antibiotics are manda-
tory. 
In India genital tuberculosis appears to be an im-
portant and common cause of IUA causing pri-
mary and secondary infertility with various 
grades of adhesions (Sharma et al. 2008) and so 
it is important to investigate the patients who 
come from those areas. 
 
2.1 Hormonal therapy 
 
Already in 1964 Wood and Pena hypothesized 
the beneficial effects of estrogen therapy on en-
dometrial regeneration after surgical treatment 
for IUAs (Wood and Pena 1964). Postoperative 
treatment with estrogen in order to promote the 
regeneration of the endometrium has been rec-
ommended in several studies, either as estrogen 
only (Capella-Allouc et al. 1999; Dawood, Al-
Talib, and Tulandi 2010), either with IUD 
(March, Israel, and March 1978; Chen et al. 2017; 
Yu et al. 2016; Roy et al. 2014; Zikopoulos et al. 
2004; Myers and Hurst 2012; Salma et al. 2014; 
Liu et al. 2019) or Foley catheter (Dawood, Al-
Talib, and Tulandi 2010; March, Israel, and 
March 1978; Salma et al. 2014). 
In several studies different regimens consisting 
of estrogen with or without a progestogen have 
been used (Kodaman and Arici 2007). There are 
no comparative studies that examine dosage, ad-
ministration or combinations of hormones (But-
tram et al. 1988). In a recent randomized study, 
4 mg and 10 mg estradiol orally was compared. 
No superior effect of the high dosage was 
demonstrated (Liu et al. 2019). When comparing 
2 mg and 6 mg in a prospective randomized trial, 
no benefit was demonstrated in the 6 mg arm. 
In the randomized controlled trials of Farhi et al, 
60 women undergoing dilatation and curettage 
during the first trimester of pregnancy were allo-
cated to receive estrogen combined with proges-
togen or no treatment (Farhi et al. 1993). The 
authors have found that women in the interven-
tion group had a significantly thicker endome-
trium compared with women in the control 
group (8.4 with intervention vs 6.7 mm with no 
treatment; P = 0.02) and so they concluded that 
postoperative hormonal treatment may be useful 
for IUAs prevention following curettage. Never-
theless, but this study does not report the data 
about pregnancy rates and IUAs recurrence 
(Farhi et al. 1993). The systematic review of Jo-
hary et al, concluded that estrogen therapy, may 
be beneficial for women with IUAs, but as ad-
junctive therapy combined with other anti‐adhe-
sion strategies (Johary et al. 2014). Also, in three 
prospective randomized studies, the administra-
tion of oral estrogen did not reduce the risk of 
IUAs (Tonguc et al. 2010; Dabirashraft et al. 
1996; Roy et al. 2014). 
 
3. Future perspective 
Recently, some experimental study has demon-
strated that stem cells on rat models is a promis-
ing therapeutic approach for the regeneration of 
the inadequate endometrium. In particular, 
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Zhao’s study aimed to identify exosomes derived 
from adipose-derived mesenchymal stem cells 
(ADSC-exo) and explore the therapeutic poten-
tial in IUA rat models. In IUA model, treatment 
with ADSC-exo maintained normal uterine 
structure, promoted endometrial regeneration 
and collagen remodeling, and enhanced the ex-
pression of integrin-β3, LIF, and VEGF. An im-
proved receptivity of the regenerated endome-
trium was confirmed. Their findings demon-
strated that ADSC-exo promoted endometrial 
regeneration and fertility restoration. It sug-
gested that topical administration of ADSC-exo 
in uterus could be a promising strategy for pa-
tients suffering severe intrauterine adhesions and 
infertility (Zhao et al. 2020). 
Another studies on rat model of Zhang at al eval-
uated urinary bladder matrix in order to improve 
endometrial regeneration, receptivity and fertility 
(H. Zhang et al. 2020). 
Another promising research of Zhang SS, based 
on the synergistic effect of the well-known E2 
and the Heparin-Poloxamer Hydrogel, revealed 
that administrating E2-HP hydrogel to injured 
uterus had a positive effect on endometrium re-
generation in rat model (S. Zhang et al. 2020).  
In the only prospective study performed on hu-
mans by Santamaria et al. 16 women with IUA 
confirmed by hysteroscopy were treated with 
uterine intravascular infusion of bone marrow-
derived stem cell (BMDSC). During the follow-
up period, menstrual function returned to nor-
mal within 6 months after BMDSC infusion, 
with three spontaneous pregnancy and seven 
pregnancies after IVF and embryo transfer re-
ported (Santamaria et al. 2016). These novel 
studies begin to open the door for further pro-




Currently, there is no ideal method to prevent 
IUAs and it is difficult to standardize a therapy 
valid for all patients as IUAs is a heterogeneous 
syndrome with specific peculiarities. 
Many devices, used alone or in combination, 
have been proposed to prevent IUAs formation 
after intrauterine procedures, but at present it is 
difficult to establish which approach is the best, 
due to the heterogeneity of the studies, the con-
trasting results reported, and the different out-
comes investigated. To avoid the adhesions re-
lapse, it would seem to be recommendable the 
use of balloon catheters and IUD with adjunc-
tive estrogen therapy. The combination strategy 
that using physical barriers as the delivery carri-
ers for therapeutics might provide new alterna-
tives for the prevention of IUAs.  
Recently several new methods have been pa-
tented to prevent IUAs but long-term results are 
not yet available. More research is needed to as-
sess the best approach to prevent adhesions in 
order to increase reproductive chances and if 
pregnancy occurs to reduce obstetrics risk such 
as miscarriage, preterm birth, abnormal placen-
tation, intrauterine growth restriction. 
Perhaps there is the key to improving the out-
come of IUAs: the personalization of therapy 
and the evolution of biocompatible materials 
that are increasingly adaptable to specific needs. 
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